Australian regenerative medicine company Orthocell (ASX:OCC) has announced the appointment of Dr Christopher Dy and Dr David Brogan to its medical and scientific advisory board (MSAB).
Orthocell managing director Paul Anderson said, “We are delighted to welcome Professors Dy and Brogan to the Orthocell MSAB. Both are globally recognised nerve reconstructive surgeons, with a passion for translating medical research and delivering the highest quality patient care.
"We are also delighted to be collaborating with Washington University, one of the leading centres for nerve reconstructive surgery in the USA. These appointments, along with the recent appointment of Dr Ravi Thadhani to the Orthocell board of directors, adds significant depth to our US team and ability to execute our commercialisation plans."
Both professors are orthopaedic surgeons, specialising in the treatment of nerve injuries, while also leading a comprehensive research program that is directly relevant to patients, clinicians, scientists, and policy-makers.
Their translational research is focused on the epidemiologic, economic, and clinical analysis of peripheral and brachial plexus nerve injuries.
They are based at Washington University. It has affiliations with 26 Nobel laureates in economics, physiology and medicine, chemistry, and physics.
The company said the appointments will assist it in the design and implementation of the US-focused development strategy (pre-clinical and clinical) for the nerve repair regulatory and market access program.